Posts

Posted on

Simon Property Group Declares Fourth Quarter 2020 Dividend of $1.30 Per Common Share

PR Newswire

INDIANAPOLIS, Dec. 15, 2020 /PRNewswire/ — Simon, a real estate investment trust engaged in the ownership of premier shopping, dining, entertainment and mixed-use destinations, today announced a common stock dividend for the fourth quarter 2020. 

Simon’s Board of Directors has declared a $1.30 per common share dividend, payable in cash, for the fourth quarter 2020.  The dividend will be payable on January 22, 2021 to shareholders of record at the close of business on December 24, 2020.    


Forward-Looking Statements

Certain statements made in this press release may be deemed “forward–looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Although the Company believes the expectations reflected in any forward–looking statements are based on reasonable assumptions, the Company can give no assurance that its expectations will be attained, and it is possible that the Company’s actual results may differ materially from those indicated by these forward–looking statements due to a variety of risks, uncertainties and other factors. Such factors include, but are not limited to: uncertainties regarding the impact of the COVID-19 pandemic and governmental restrictions intended to prevent its spread on our tenants’ businesses, financial condition, results of operations, cash flow and liquidity and our ability to access the capital markets, satisfy our debt service obligations and make distributions to our stockholders; the inability to collect rent due to the bankruptcy or insolvency of tenants or otherwise; changes in economic and market conditions that may adversely affect the general retail environment; the intensely competitive market environment in the retail industry; changes to applicable laws or regulations or the interpretation thereof; risks associated with the acquisition, development, redevelopment, expansion, leasing and management of properties; the inability to lease newly developed properties and renew leases and relet space at existing properties on favorable terms; the potential loss of anchor stores or major tenants; decreases in market rental rates; the impact of our substantial indebtedness on our future operations; any disruption in the financial markets that may adversely affect our ability to access capital for growth and satisfy our ongoing debt service requirements; any change in our credit rating; changes in market rates of interest and foreign exchange rates for foreign currencies; general risks related to real estate investments, including the illiquidity of real estate investments; security breaches that could compromise our information technology or infrastructure; risks relating to our joint venture properties; our continued ability to maintain our status as a REIT; changes in tax laws or regulations that result in adverse tax consequences; changes in the value of our investments in foreign entities; our ability to hedge interest rate and currency risk; changes in insurance costs; the availability of comprehensive insurance coverage; natural disasters; the potential for terrorist activities; environmental liabilities; the loss of key management personnel; and the transition of LIBOR to an alternative reference rate. The Company discusses these and other risks and uncertainties under the heading “Risk Factors” in its annual and quarterly periodic reports filed with the SEC.  The Company may update that discussion in subsequent other periodic reports, but except as required by law, the Company undertakes no duty or obligation to update or revise these forward-looking statements, whether as a result of new information, future developments, or otherwise.

About Simon

Simon is a real estate investment trust engaged in the ownership of premier shopping, dining, entertainment and mixed-use destinations and an S&P 100 company (Simon Property Group, NYSE: SPG). Our properties across North America, Europe and Asia provide community gathering places for millions of people every day and generate billions in annual sales.

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/simon-property-group-declares-fourth-quarter-2020-dividend-of-1-30-per-common-share-301193434.html

SOURCE Simon

Posted on

Keurig Dr Pepper Announces Appointment of New Director to its Board

PR Newswire

BURLINGTON, Mass. and PLANO, Texas, Dec. 15, 2020 /PRNewswire/ — Keurig Dr Pepper Inc. (NASDAQ: KDP) announced today that Justine Tan, currently a partner at JAB since early 2020, has been elected as a director to the KDP board, effective December 9, 2020.  Prior to her role at JAB, Tan served at Temasek from 2012 to 2019, as a founding member of the firm’s US operations, and, prior to that, she was an investment banker at Goldman Sachs. Tan will fill the seat vacated by Fabian Simon, who resigned from the KDP board on September 7, 2020, upon his appointment as Chief Executive Officer of JDE Peet’s.  

The Company also announced today that Anna-Lena Kamenetzky, previously a JAB partner who left the firm earlier this year, has stepped down from the KDP board effective December 9, 2020.  

Commenting on the announcement, KDP Chairman and CEO Bob Gamgort stated, “We are pleased to welcome Justine to KDP’s board of directors. With more than 20 years of experience in investing, banking and operations, Justine will be a strong partner on our board. We also thank Anna-Lena for her service as a KDP director since the merger and wish her well.”


KDP Contacts


Tyson Seely (Investors)
T: 781-418-3352 / [email protected]

Steve Alexander (Investors)
T: 972-673-6769 / [email protected]

Katie Gilroy (Media)
T: 781-418-3345 / [email protected] 

About Keurig Dr Pepper
Keurig Dr Pepper (KDP) is a leading beverage company in North America, with annual revenue in excess of $11 billion and nearly 26,000 employees. KDP holds leadership positions in soft drinks, specialty coffee and tea, water, juice and juice drinks and mixers, and markets the #1 single serve coffee brewing system in the U.S. and Canada. The Company’s portfolio of more than 125 owned, licensed and partner brands is designed to satisfy virtually any consumer need, any time, and includes Keurig®, Dr Pepper®, Green Mountain Coffee Roasters®, Canada Dry®, Snapple®, Bai®, Mott’s®, CORE® and The Original Donut Shop®. Through its powerful sales and distribution network, KDP can deliver its portfolio of hot and cold beverages to nearly every point of purchase for consumers.  The Company is committed to sourcing, producing and distributing its beverages responsibly through its Drink Well. Do Good. corporate responsibility platform, including efforts around circular packaging, efficient natural resource use and supply chain sustainability.

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/keurig-dr-pepper-announces-appointment-of-new-director-to-its-board-301193362.html

SOURCE Keurig Dr Pepper

Posted on

Albemarle Receives Sustainable Business Award for Charlotte Headquarters Expansion Project

PR Newswire

CHARLOTTE, N.C., Dec. 15, 2020 /PRNewswire/ — Albemarle Corporation (NYSE: ALB), a leader in the global specialty chemicals industry, announced today it has been awarded the Carolinas Community Design Award by the U.S. Green Building Council (USGBC) for its headquarters expansion project in Charlotte, N.C.

Albemarle won this award in the Interior Design and Construction category for the company’s sustainable, collaborative, and wellness-focused headquarters expansion. This award comes on the heels of the company receiving a LEED® Gold certification from the USGBC earlier this year for the same project.

“At Albemarle, sustainability and collaboration are key areas of focus in how we work and live,” said John Gifford, Albemarle Director of Global Real Estate and Facilities. “To receive this award from the USGBC, in addition to our LEED Gold certification, means they recognize the importance we place on those critical attributes to our employees’ work environment. Thank you to our dedicated project team and partners for bringing Albemarle’s values to life.”

The Albemarle headquarters expansion project, completed in January 2019, features approximately 141,000 square feet of office space spread over six floors of the North Tower building in the Capitol Towers development located in Charlotte’s SouthPark neighborhood. Partners on the expansion project include Lincoln Harris, property and project construction manager; Preferred Office Properties Capitol Towers, property owner; LS3P, architectural design; Tyler 2, building and construction services; and Ecoimpact Consulting, LEED consultant.

About Albemarle

Albemarle Corporation (NYSE: ALB), headquartered in Charlotte, N.C., is a global specialty chemicals company with leading positions in lithium, bromine and refining catalysts. We think beyond business-as-usual to power the potential of companies in many of the world’s largest and most critical industries, such as energy, electronics, and transportation. We actively pursue a sustainable approach to managing our diverse global footprint of world-class resources. In conjunction with our highly experienced and talented global teams, our deep-seated values, and our collaborative customer relationships, we create value-added and performance-based solutions that enable a safer and more sustainable future.

We regularly post information to www.albemarle.com, including notification of events, news, financial performance, investor presentations and webcasts, non-GAAP reconciliations, SEC filings and other information regarding our company, its businesses and the markets it serves.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/albemarle-receives-sustainable-business-award-for-charlotte-headquarters-expansion-project-301193451.html

SOURCE Albemarle Corporation

Posted on

GoDaddy Acquires Poynt, Expands Commerce Services with Offline Sales and Integrated Payments

GoDaddy’s Commerce Platform Enables Small Businesses to Sell Everywhere by Connecting Online and Offline Shopping Experiences

Acquisition expected to contribute more than $150 million of bookings in 2023

PR Newswire

SCOTTSDALE, Ariz., Dec. 15, 2020 /PRNewswire/ — GoDaddy Inc. (NYSE: GDDY), the company that empowers everyday entrepreneurs, today announced it has entered into a definitive agreement to acquire Poynt. Under the terms of the agreement, GoDaddy will pay $320 million in cash at closing and $45 million in deferred cash payments subject to certain performance and employment conditions over three years. The transaction is expected to close in the first quarter of 2021, subject to the satisfaction of regulatory approvals and other customary closing conditions.

“Commerce is critical to our customers and we continue to invest in building seamlessly intuitive experiences that enable small businesses to sell everywhere,” said GoDaddy CEO Aman Bhutani. “Poynt accelerates our strategy to provide a complete suite of commerce and payment services to address this critical customer need and focus on a large addressable market opportunity. We’ve built leading e-commerce capabilities that today allow small businesses to easily sell on their sites, across major marketplaces and the most popular social networks, and now we will help make them successful everywhere.”

Connecting Online and In-Person Commerce

The rapid convergence of online and in-person consumer shopping is accelerating the need for small businesses to provide connected commerce experiences across all channels for their customers. Integrating Poynt with GoDaddy’s Websites + Marketing and WordPress commerce services will enable small businesses to boost sales and customer satisfaction by seamlessly bridging both online and offline shopping experiences.

With global distribution via reseller partnerships, Poynt is used by more than 100,000 merchants with over $16 billion in annual Gross Merchandise Volume (GMV). Poynt offers a complete suite of products needed for small businesses to sell and accept payments anywhere – spanning point-of-sale (POS) systems, payments, invoicing, loyalty and rewards programs, and transaction management.  

“Poynt has spent the past seven years building the most advanced connected commerce platform on the market,” said Poynt CEO Osama Bedier. “Our team is super excited to join forces and help millions of GoDaddy entrepreneurs sell everywhere, in the most seamless experience possible, at a time they couldn’t need it more.”

Poynt’s range of patented Android-based smart POS terminals, and PoyntOS powered third-party terminals, deliver advanced in-person capabilities that drive merchant and consumer engagement. Poynt also provides mobile app and web/desktop software for POS, invoicing and virtual terminals. Additionally, Poynt offers a range of payment processing models for small businesses, including integration with 16 different payment processors, featuring the top five US banks, and offers Poynt Payments in the US built in partnership with Elavon/US Bank. 

Post close, Poynt CEO Osama Bedier will join the GoDaddy leadership team reporting to GoDaddy CEO Aman Bhutani and lead a new Commerce Division dedicated to creating the most intuitive and seamless commerce experiences for small businesses.

GoDaddy management will host a webcast today at 5:00 p.m. Eastern Time. To listen to the call, please register here for webcast information. Following completion of the call, a recording will also be available on GoDaddy’s investor relations website at https://investors.godaddy.net.

About GoDaddy
GoDaddy is empowering everyday entrepreneurs around the world by providing all of the help and tools to succeed online. With 20 million customers worldwide, GoDaddy is the place people come to name their idea, build a professional website, attract customers and manage their work. Our mission is to give our customers the tools, insights and the people to transform their ideas and personal initiative into success.

Source: GoDaddy Inc

© 2020 GoDaddy Inc. All Rights Reserved.

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/godaddy-acquires-poynt-expands-commerce-services-with-offline-sales-and-integrated-payments-301193386.html

SOURCE GoDaddy Inc.

Posted on

Gilead and Galapagos Announce New Commercialization and Development Agreement for Jyseleca® (Filgotinib)

Gilead and Galapagos Announce New Commercialization and Development Agreement for Jyseleca® (Filgotinib)

— Gilead will Not Advance Jyseleca for the Treatment of Rheumatoid Arthritis (RA) in the U.S. Following FDA Type A Meeting —

— Galapagos to Assume Sole Responsibility in Europe for Jyseleca in RA and Ulcerative Colitis (UC) Plus Future Indications; Gilead to Receive Royalties on European Sales Starting in 2024 —

— Galapagos to Assume Responsibility for Majority of Ongoing Clinical Trials; Gilead will Pay Galapagos €160 million to Support Ongoing Development and Accelerated Commercial Buildout in EU —

FOSTER CITY, Calif. & MECHELEN, Belgium–(BUSINESS WIRE)–
Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & Nasdaq: GLPG) today announced that the companies have agreed to amend their existing arrangement for the commercialization and development of Jyseleca (filgotinib). This announcement follows a Type A meeting with the U.S. Food and Drug Administration (FDA) to discuss the points raised in the Complete Response Letter (CRL) related to the New Drug Application (NDA) for filgotinib in the treatment of RA.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201215006105/en/

Based on the feedback received from the FDA during the NDA review process and in the Type A meeting, Gilead will not pursue FDA approval of filgotinib for RA. While both Gilead and Galapagos continue to believe in the clinical profile of the 200 mg dose, Gilead has concluded that this dose is required to be competitive in RA in the United States and that the 200 mg dose is unlikely to achieve approval for RA in the U.S. without conducting substantial additional clinical studies.

Under the new arrangement between the companies, Galapagos will assume sole responsibility in Europe for filgotinib in RA, where 200 mg and 100 mg doses are approved for the treatment of moderate to severe RA, and in all future indications. Galapagos will receive payments from Gilead in connection with changes in responsibility for the commercialization and development of filgotinib in Europe and Gilead will receive royalties from European sales of filgotinib. This is an acceleration of the commercial strategy in place for products under the separate ten-year research and development collaboration between the companies, where Galapagos is also responsible for European commercialization.

Through a phased transition including the transfer of filgotinib’s marketing authorization to Galapagos, the majority of activities supporting filgotinib in Europe are expected to be assumed by Galapagos by the end of 2021. Under the new operating model, Gilead will retain commercial rights and remain marketing authorization holder for filgotinib outside of Europe, including in Japan where filgotinib has recently been approved, and is co-marketed with Eisai.

“While we believe that the clinical profile of Jyseleca could help many patients living with RA, we no longer see a viable path to U.S. approval in this indication,” said Daniel O’Day, Chairman and Chief Executive Officer, Gilead Sciences. “In this new context, Gilead and Galapagos believe it makes sense for Galapagos to drive commercialization in Europe. We are confident that through our strategic alliance with Galapagos, we will deliver many important new therapies for inflammatory diseases in the future.”

“Jyseleca is already providing an important new treatment option, making a difference to the lives of patients living with RA, where it is available in Europe,” said Onno van de Stolpe, Chief Executive Officer of Galapagos. “While we are very disappointed by the outcome of the FDA meeting, we are excited that we can now accelerate the plan for Galapagos to lead on commercial activities in Europe in our ongoing collaboration with Gilead, and fully leverage the commercial organization Galapagos has built for the Jyseleca launch. This is an important new chapter in Galapagos’ ongoing journey to be a leading European biotech company in inflammation and fibrosis.”

Filgotinib Development

Under the terms of the amended agreement, Galapagos will assume operational responsibility for ongoing clinical trials evaluating filgotinib in RA. Gilead and Galapagos recently paused clinical trials of filgotinib in psoriatic arthritis (PsA), ankylosing spondylitis (AS), and non-infectious uveitis following receipt of the CRL and, without a viable path forward in the United States, the companies no longer believe it is feasible to continue the current global development program for filgotinib in these indications. As a result, these trials will be stopped over the coming months.

Week 26 data from the MANTA and MANTA-RAy studies, including primary and key secondary endpoints, will be available by mid-2021 and the parties expect to submit the data to regulatory authorities shortly thereafter. In order to complete their review of filgotinib in RA or other future indications,the FDA has requested up to Week 52 follow-up data for patients who show >50% decrease in semen parameters by Week 26 and do not recover in the ongoing MANTA and MANTA-RAy studies.

Gilead and Galapagos will continue to investigate the potential for filgotinib to support patients living with Inflammatory Bowel Disease (IBD). Gilead will retain operational responsibility for the current trials in Crohn’s disease while Galapagos will assume operational responsibility for ongoing trials in UC. Filgotinib is currently under review by the European Medicines Agency (EMA) for the treatment of UC and is expected to be submitted to the Japanese Ministry of Health, Labour and Welfare in the first half of 2021. Gilead and Galapagos expect to have further clarity on the potential U.S. filing of filgotinib in IBD, after consultation with FDA, including on the results of the MANTA and MANTA-RAy studies as described above.

Financial Terms of the Agreement

Under the terms of the new arrangement, Galapagos will assume all development, manufacturing, commercialization and certain other rights for filgotinib in Europe. The transfer will be subject to applicable local legal, regulatory and consultation requirements. The parties intend to transfer most activities by December 31, 2021 and complete the transition by December 31, 2022. Beginning on January 1, 2021, Galapagos will bear the future development costs for certain studies, in lieu of the equal cost split contemplated by the previous agreement. These studies include the DARWIN3, FINCH4, FILOSOPHY, and Phase 4 studies and registries in RA, MANTA and MANTA-RAy, the PENGUIN1 and 2 and EQUATOR2 studies in PsA, the SEALION1 and 2 studies in AS, the HUMBOLDT study in uveitis in addition to other clinical and non-clinical expenses supporting these studies and support for any investigator sponsored trials in non-IBD conditions and non-clinical costs on all current trials. The existing 50/50 global development cost sharing arrangement will continue for the following studies: SELECTION and its long-term extension study (LTE) in UC, DIVERSITY and its LTE, DIVERGENCE 1 and 2 and their LTEs and support for Phase 4 studies and registries in Crohn’s disease, pediatric studies and their LTEs in RA, UC and Crohn’s disease, and support for investigator sponsored trials in IBD.

All commercial economics on filgotinib in Europe will transfer to Galapagos as of January 1, 2022, subject to payment of tiered royalties of 8 to 15 percent of net sales in Europe to Gilead, starting in 2024. In connection with the amendments to the existing arrangement for the commercialization and development of filgotinib, Gilead has agreed to irrevocably pay Galapagos €160 million, which will be split between a €110 million payment in 2021 and a €50 million payment in 2022 and is subject to certain adjustments for higher than budgeted development costs. In addition, Galapagos will no longer be eligible to receive any future milestone payments relating to filgotinib in Europe. Gilead expects to recognize the full amount of these payments in its R&D expenses in the fourth quarter of 2020.

Information on Related Party Transaction

The following information is provided by Galapagos pursuant to article 7:116, paragraph 4 of the Belgian Companies and Association Code in connection with the term sheet that has been entered into between Gilead Sciences, Inc. and Galapagos NV on 15 December 2020. For a summary of the main terms of the term sheet and the amended terms of the parties’ existing agreement for the commercialization and future development of filgotinib, see above in this press release. These terms and amendments will be reflected in new agreements that will be entered into by Gilead and Galapagos on the basis of the term sheet.

Gilead has two representatives on the supervisory board of Galapagos (Daniel O’Day and Linda Higgins). In addition, Gilead holds (indirectly, through one of its subsidiaries) more than 25% of the shares in Galapagos. Hence, Gilead is considered a “related party” of Galapagos in accordance with the International Financial Reporting Standards as adopted by the European Union. In view hereof, the supervisory board of Galapagos applied the procedure of article 7:116 of the Belgian Companies and Association Code in connection with the approval of term sheet with Gilead. The two representatives of Gilead on the supervisory board of Galapagos did not participate in the deliberation and voting by the supervisory board in relation to the term sheet.

Within the context of the aforementioned procedure, a committee of three independent members of the supervisory board of Galapagos (the Committee) issued an advice to the supervisory board in which the Committee assessed the term sheet. In its advice to the supervisory board, the Committee concluded the following: “The Committee believes that under the circumstances the proposed amendments to Filgotinib Agreements are in the interest of Galapagos and all of its shareholders, and fully aligned with the long-term strategy of Galapagos. The proposed amendments offer an important opportunity to accelerate the plan for Galapagos to lead on commercial activities in Europe for future compounds in its ongoing R&D collaboration with Gilead, and to bolster and further leverage the commercial organization Galapagos has built for the launch of filgotinib. The return of the rights and responsibilities for filgotinib to Galapagos also comes with a number of challenges and risks in terms execution and operation, but these are not unreasonable and can be managed going forward. The Committee therefore believes that the proposed amendments to the collaboration with Gilead, are in the interest of Galapagos, and in any event not manifestly abusive. In view hereof, the Committee issues a favorable and unqualified opinion to the supervisory board of Galapagos.” The supervisory board did not deviate from the Committee’s advice.

The assessment by the statutory auditor of Galapagos of the advice of the committee and the minutes of the supervisory board is as follows: “Based on our review, we have noted no material inconsistency between the accounting and financial information included in the minutes of the supervisory board and in the advice of the ad hoc committee of the independent members of the supervisory board compared to the information that we, as the Company’s statutory auditor, have within the framework of our mandate.”

About Jyseleca (filgotinib)

Filgotinib is approved and marketed as Jyseleca (200 mg and 100 mg tablets) in Europe and Japan for the treatment of adults with moderately to severely active RA who have responded inadequately or are intolerant to one or more disease modifying anti-rheumatic drugs (DMARDs). Filgotinib may be used as monotherapy or in combination with methotrexate (MTX). The European Summary of Product Characteristics for filgotinib, which includes contraindications and special warnings and precautions, is available at www.ema.europa.eu. The interview form from the Japanese Ministry of Health, Labour and Welfare is available at www.info.pmda.go.jp. Filgotinib was submitted to the European Commission for an extended indication for the treatment of adults with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent.

About Gilead Sciences

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California. For more information on Gilead Sciences, please visit the company’s website at www.gilead.com.

About Galapagos

Galapagos NV discovers, develops and commercializes small molecule medicines with novel modes of action, several of which show promising patient results and are currently in late-stage development in multiple diseases. Our pipeline comprises discovery through Phase 3 programs in inflammation, fibrosis and other indications. Our ambition is to become a leading global biotech company focused on the discovery, development and commercialization of innovative medicines. More information at www.glpg.com.

This press release contains inside information within the meaning of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation).

Gilead Forward-Looking Statement

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, related to Gilead, Galapagos, the filgotinib collaboration and the ten-year research and development collaboration that are subject to risks, uncertainties and other factors, including the ability of the companies to complete the transaction in a timely manner or at all, including the ability to successfully transition the commercialization of filgotinib in Europe from Gilead to Galapagos in the anticipated timelines; difficulties or unanticipated expenses in connection with implementing the transaction; the risk that Gilead may not realize any anticipated benefits from the collaborations; the potential effects on Gilead’s revenues and earnings; the ability of the companies to discover, develop and commercialize any products under the collaborations, including the ability of the companies to commercialize filgotinib or develop and commercialize filgotinib for additional indications; the ability of the companies to initiate and complete clinical trials involving any product candidates under the collaborations, including filgotinib, in the currently anticipated timelines or at all; the possibility of unfavorable results from ongoing and additional clinical trials involving any product candidates under the collaborations, including filgotinib; uncertainties relating to regulatory applications and related filing and approval timelines, including the risk that EMA may not approve filgotinib for the treatment of UC in the anticipated timelines or at all, and any marketing approvals, if granted, may have significant limitations on its use; the possibility that the companies may make a strategic decision to discontinue development of involving any product candidates under the collaborations, including filgotinib for the treatment of RA, UC, PsA, AS, non-infectious uveitis, IBD, Crohn’s disease or other indications, and as a result, such products may never be successfully commercialized; and the accuracy of any assumptions underlying any of the foregoing. These and other risks are described in detail in Gilead’s periodic reports filed with the U.S. Securities and Exchange Commission, including current reports on Form 8-K, quarterly reports on Form 10-Q and annual reports on Form 10-K. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including all statements regarding the intent, belief or current expectation of the companies and members of their senior management team. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and are cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.

Galapagos Forward-Looking Statement

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those referred to in the forward-looking statements and, therefore, the reader should not place undue reliance on them. These risks, uncertainties and other factors include, without limitation, the risk that the parties would not be able to complete the contemplated transaction in a timely manner or at all, the risk that parties may not be able to successfully implement the transaction and transfer of rights and activities in a timely or efficient manner or at all, taking into account the need to fulfil applicable local legal, regulatory and consultation requirements and other integration risks and expenses, that Galapagos’ expectations regarding the costs and revenues associated with the transfer of European commercialization rights to filgotinib may be incorrect, inherent risks associated with clinical trial and product development activities, competitive developments, and regulatory approval requirements, including the risk that data from the ongoing and planned clinical research programs with filgotinib may not support registration or further development for UC, IBD, RA, or other indications due to safety, efficacy or other reasons, the timing or likelihood of regulatory authorities’ approval of marketing authorization for filgotinib for UC, IBD, RA, or other indications, including the risk of such regulatory authorities requiring additional studies, Galapagos’ reliance on collaborations with third parties, including the collaboration with Gilead, the uncertainty regarding estimates of the commercial potential of filgotinib, the risks and costs involved in selling and marketing filgotinib, the possibility that the companies may make a strategic decision to discontinue development of any product candidates under the collaborations, including filgotinib for the treatment of RA, UC, PsA, AS, non-infectious uveitis, IBD, Crohn’s disease or other indications, and as a result, such products may never be successfully commercialized, as well as those risks and uncertainties identified in our Annual Report on Form 20-F for the year ended 31 December 2019 and our subsequent filings with the SEC. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The forward-looking statements contained herein are based on management’s current expectations and beliefs and speak only as of the date hereof, and Galapagos makes no commitment to update or publicly release any revisions to forward-looking statements in order to reflect new information or subsequent events, circumstances or changes in expectations.

Jyseleca®, Gilead and the Gilead logo are trademarks of Gilead Sciences, Inc. or its related companies.

Gilead

Monica Tellado, Investors

+1 (650) 219-3882

Arran Attridge, Media

+1 (650) 425-8975

Galapagos

Elizabeth Goodwin, Investors

+1 (781) 460-1784

Carmen Vroonen, Media

+32 473 824-874

KEYWORDS: Belgium Europe United States North America California

INDUSTRY KEYWORDS: Biotechnology Hospitals Health Pharmaceutical Clinical Trials

MEDIA:

Logo
Logo
Logo
Logo
Posted on

Boston Properties Declares Regular Quarterly Dividends

Boston Properties Declares Regular Quarterly Dividends

BOSTON–(BUSINESS WIRE)–Boston Properties, Inc. (NYSE: BXP), the largest publicly-traded owner and manager of Class A office properties in the United States, announced today that its Board of Directors declared a regular quarterly cash dividend of $0.98 per share of common stock for the period October 1, 2020 to December 31, 2020 payable on January 28, 2021 to shareholders of record as of the close of business on December 31, 2020.

The Board of Directors also declared a regular quarterly cash dividend for the Company’s 5.25% Series B Cumulative Redeemable Preferred Stock (the “Series B Preferred Stock”). The cash dividend of $0.328125 per depositary share is payable on February 16, 2021 to shareholders of record as of the close of business on February 5, 2021 and covers the period from November 16, 2020 to February 15, 2021. Each depositary share represents 1/100th of a share of Series B Preferred Stock.

About Boston Properties

Boston Properties (NYSE: BXP) is the largest publicly-held developer and owner of Class A office properties in the United States, concentrated in five markets – Boston, Los Angeles, New York, San Francisco and Washington, DC. The Company is a fully integrated real estate company, organized as a real estate investment trust (REIT), that develops, manages, operates, acquires and owns a diverse portfolio of primarily Class A office space. The Company’s portfolio totals 51.2 million square feet and 196 properties, including seven properties under construction. For more information about Boston Properties, please visit our website at www.bxp.com.

AT THE COMPANY

Mike LaBelle

Executive Vice President

Chief Financial Officer

617.236.3352

Sara Buda

Vice President, Investor Relations

[email protected]

617.236.3429

KEYWORDS: United States North America Massachusetts

INDUSTRY KEYWORDS: Commercial Building & Real Estate Construction & Property REIT

MEDIA:

Posted on

Pebblebrook Hotel Trust Announces Exercise In Full of Underwriters’ Over-allotment Option and Subsequent Closing of Public Offering of 1.75% Convertible Senior Notes Due 2026

Pebblebrook Hotel Trust Announces Exercise In Full of Underwriters’ Over-allotment Option and Subsequent Closing of Public Offering of 1.75% Convertible Senior Notes Due 2026

BETHESDA, Md.–(BUSINESS WIRE)–
Pebblebrook Hotel Trust (NYSE: PEB) (the “Company”) today announced that it has closed its previously announced underwritten public offering of $500,000,000 aggregate principal amount of its 1.75% Convertible Senior Notes due 2026 (the “Notes”), including $50,000,000 aggregate principal amount of Notes sold pursuant to the exercise in full of the underwriters’ over-allotment option to purchase additional Notes.

The Notes are the Company’s senior unsecured obligations and rank equally with all of its existing and future unsecured debt that is not subordinated, senior to any future subordinated debt and junior to all existing and future debt and preferred equity of the Company’s subsidiaries. The Notes pay interest semiannually at a rate of 1.75% per annum and will mature on December 15, 2026. The Notes have an initial conversion rate of 39.2549 per $1,000 principal amount of the Notes (equivalent to a conversion price of approximately $25.47 per common share of the Company (“Common Shares”) and a conversion premium of approximately 35.0% based on the closing price of $18.87 per Common Share on December 10, 2020). The initial conversion rate of the Notes is subject to adjustment upon the occurrence of certain events, but will not be adjusted for any accrued and unpaid interest. Prior to June 15, 2026, the Notes are convertible only upon certain circumstances and during certain periods, and thereafter will be convertible at any time prior to the close of business on the second scheduled trading day prior to maturity of the Notes. Upon conversion, holders will receive cash, Common Shares or a combination thereof at the Company’s election.

In connection with the pricing of the Notes, the Company entered into privately negotiated capped call transactions with certain of the underwriters or their respective affiliates and other financial institutions (the “Option Counterparties”). The capped call transactions cover, subject to customary adjustments, the number of Common Shares underlying the Notes. The capped call transactions are generally expected to reduce the potential dilution to Common Shares upon any conversion of the Notes and/or offset any cash payments the Company is required to make in excess of the principal amount of such converted Notes, as the case may be, with such reduction and/or offset subject to a cap. The cap price of the capped call transactions was initially approximately $33.0225, which represents a premium of approximately 75.0% over the last reported sale price of Common Shares on the New York Stock Exchange on December 10, 2020, and is subject to certain adjustments under the terms of the capped call transactions.

The Option Counterparties or their respective affiliates may modify their hedge positions by entering into or unwinding various derivatives with respect to Common Shares and/or purchasing or selling Common Shares or other securities of the Company in secondary market transactions prior to the maturity of the Notes (and are likely to do so following any conversion, repurchase, or redemption of the Notes, to the extent the Company exercises the relevant election under the capped call transactions). This activity could also cause or avoid an increase or a decrease in the market price of Common Shares or the Notes, which could affect the ability of holders to convert the Notes. To the extent the activity occurs during any observation period related to a conversion of the Notes, it could also affect the number of Common Shares and value of the consideration that holders will receive upon conversion of the Notes.

The Company used a portion of the net proceeds from the offering of the Notes to pay the cost of the capped call transactions, including the additional capped call transactions the Company entered into pursuant to the exercise in full of the underwriters’ over-allotment option to purchase additional Notes. The Company contributed the remainder of the net proceeds to its operating partnership. The operating partnership will use the net proceeds to reduce amounts outstanding under the Company’s senior unsecured revolving credit facility and unsecured term loans.

BofA Securities and Raymond James acted as the joint book-running managers of the offering. Truist Securities, US Bancorp, PNC Capital Markets LLC and Regions Securities LLC acted as the co-lead managers of the offering. Capital One Securities, BMO Capital Markets, Scotiabank, SMBC Nikko, TD Securities and BBVA acted as the co-managers of the offering.

About Pebblebrook Hotel Trust

Pebblebrook Hotel Trust (NYSE: PEB) is a publicly traded real estate investment trust (“REIT”) and a leading owner of urban and resort lifestyle hotels in the United States. The Company owns 53 hotels, totaling approximately 13,200 guest rooms across 14 urban and resort markets with a focus on the west coast gateway cities.

Raymond D. Martz, Chief Financial Officer, Pebblebrook Hotel Trust – (240) 507-1330

KEYWORDS: Maryland United States North America

INDUSTRY KEYWORDS: Professional Services Commercial Building & Real Estate Lodging Finance Construction & Property Travel REIT

MEDIA:

Logo
Logo
Posted on

The Hackett Group Announces Change In Fourth Quarter Dividend Payment Date To December 30, 2020

The Hackett Group Announces Change In Fourth Quarter Dividend Payment Date To December 30, 2020

MIAMI–(BUSINESS WIRE)–
The Hackett Group, Inc. (NASDAQ: HCKT), a global intellectual property-based strategic consultancy and leading enterprise benchmarking and best practices digital transformation firm, today announced that the payment date for its quarterly dividend of 9.5 cents per share for its shareholders of record on December 18, 2020 has been changed to December 30, 2020 from January 9, 2021. The record date will remain December 18, 2020.

About The Hackett Group

The Hackett Group (NASDAQ: HCKT) is an intellectual property-based strategic consultancy and leading enterprise benchmarking and best practices digital transformation firm to global companies, with offerings that include cloud ERP, EPM and analytics implementation. Services include business transformation, enterprise analytics and global business services. The Hackett Group also provides dedicated expertise in business strategy, operations, finance, human capital management, strategic sourcing, procurement and information technology, including its distinguished Oracle, SAP, Coupa and OneStream practices.

The Hackett Group has completed nearly 18,000 benchmarking studies with major corporations and government agencies, including 93% of the Dow Jones Industrials, 90% of the Fortune 100, 83% of the DAX 30 and 57% of the FTSE 100. These studies drive Hackett’s Digital Transformation Platform which includes the firm’s benchmarking metrics, best practices repository and best practice configuration guides and process flows, which enable The Hackett Group’s clients and partners to achieve digital world-class performance.

More information on The Hackett Group is available at: www.thehackettgroup.com, [email protected], or by calling (770) 225-3600.

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and involve known and unknown risks, uncertainties and other factors that may cause The Hackett Group’s actual results, performance or achievements to be materially different from the results, performance or achievements expressed or implied by the forward-looking statements. Factors that impact such forward-looking statements include, among others, the impact of the coronavirus pandemic, including the duration and severity of the pandemic, the economic impact of the pandemic and the timing of an economic recovery, our ability to manage our business and capital resources through the pandemic, the ability of our products, services, or offerings mentioned in this release to deliver the desired effect, our ability to retain existing business, our ability to attract additional business, our ability to effectively market and sell our product offerings and other services, including those referenced above, the timing of projects and the potential for contract cancellations by our customers, especially given that our clients are also impacted by the coronavirus pandemic, changes in expectations regarding the business consulting and information technology industries, our ability to attract and retain skilled employees, possible changes in collections of accounts receivable due to the bankruptcy or financial difficulties of our customers, risks of competition, price and margin trends, foreign currency fluctuations, the impact of Brexit on our business, changes in general economic conditions and interest rates, our ability to mitigate the impact of the recent decline in our European operations, our ability to obtain debt financing through additional borrowings under our existing credit facility as well as other risks detailed in our Annual Report on Form 10-K for the most recent fiscal year and our Quarterly Report on Form 10-Q for the second fiscal quarter of fiscal 2020, each as filed with the Securities and Exchange Commission. We undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Robert A. Ramirez, CFO, 305-375-8005 or [email protected]

KEYWORDS: United States North America Florida

INDUSTRY KEYWORDS: Professional Services Data Management Technology Software Networks Consulting Internet

MEDIA:

Posted on

Ladder Capital Corp Announces Fourth Quarter 2020 Dividend to Holders of Class A Common Stock

Ladder Capital Corp Announces Fourth Quarter 2020 Dividend to Holders of Class A Common Stock

NEW YORK–(BUSINESS WIRE)–
Ladder Capital Corp (“Ladder” or the “Company”) (NYSE: LADR) today announced the declaration by its Board of Directors of a fourth quarter 2020 dividend of $0.20 per share of Class A common stock. The cash dividend is payable on January 15, 2021 to stockholders of record as of the close of business on December 31, 2020.

About Ladder

Ladder Capital Corp is an internally-managed commercial real estate investment trust with over $6 billion of assets. Our investment objective is to preserve and protect shareholder capital while producing attractive risk-adjusted returns. As one of the nation’s leading commercial real estate capital providers, we specialize in underwriting commercial real estate and offering flexible capital solutions within a sophisticated platform.

Ladder originates and invests in a diverse portfolio of commercial real estate and real estate-related assets, focusing on senior secured assets. Our investment activities include: (i) our primary business of originating senior first mortgage fixed and floating rate loans collateralized by commercial real estate with flexible loan structures; (ii) investing in investment grade securities secured by first mortgage loans on commercial real estate; and (iii) owning and operating commercial real estate, including net leased commercial properties.

Founded in 2008, and led by Brian Harris, the Company’s Chief Executive Officer, Ladder is run by a highly experienced management team with extensive expertise in all aspects of the commercial real estate industry, including origination, credit, underwriting, structuring, capital markets and asset management. Members of Ladder’s management and Board of Directors are highly aligned with the Company’s investors, owning over 10% of the Company’s equity.

Forward-Looking Statements and Coronavirus Risk

Certain statements in this release may constitute “forward-looking” statements. These statements are based on management’s current opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results. These forward-looking statements are only predictions, not historical fact, and involve certain risks and uncertainties, as well as assumptions. Actual results, levels of activity, performance, achievements and events could differ materially from those stated, anticipated or implied by such forward-looking statements. While Ladder believes that its assumptions are reasonable, it is very difficult to predict the impact of known factors, and, of course, it is impossible to anticipate all factors that could affect actual results, including the impact of the COVID-19 pandemic on the Company’s business. There are a number of risks and uncertainties that could cause actual results to differ materially from forward-looking statements made herein including, most prominently, the risks discussed under the heading “Risk Factors” in each of the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 and Quarterly Report on Form 10-Q for the period ended September 30, 2020, as well as its consolidated financial statements, related notes, and other financial information appearing therein, and its other filings with the U.S. Securities and Exchange Commission. Such forward-looking statements are made only as of the date of this release. Ladder expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or changes in events, conditions, or circumstances on which any such statement is based.

Investor Contact

Ladder Capital Corp Investor Relations

(917) 369-3207

[email protected]

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: REIT Finance Professional Services Commercial Building & Real Estate Construction & Property

MEDIA:

Logo
Logo
Posted on

Wantalease.com: Pickups and SUV Lease Payments Increase Entering December

CINCINNATI, Dec. 15, 2020 (GLOBE NEWSWIRE) — Wantalease.com, the nation’s first online car lease marketplace for new lease deals, reports the latest update on new lease offerings entering the month of December. While most automotive brand payments remained steady, many SUV and pickup models saw payment increases.

Among the most notable are the Ford Ranger, with a +14.86% increase from November, the Chevrolet Traverse with a +14.65% increase, and the Honda Pilot with a +11.15% increase. The Ford Ranger is offered at a payment of $325 per month, the Chevrolet Traverse is priced at $329 per month, and the Honda Pilot is also priced at $329 per month.

Other SUVs with payment increases include the Ford Expedition, Cadillac Escalade, Lexus RX, and Infiniti QX80. The Expedition increased by +6.52%, the Escalade increased by +5.46%, the RX increased by +1.92% and the QX80 increased by +1.59%.

The Nissan Sentra is currently priced the lowest of all vehicles, coming in at just $149 per month. The Sentra has held steady at the same payment for the past four months. The vehicle with the largest discount in December was the Cadillac CT5, with a decrease of -17.47%, bringing monthly payments to $349.

“We anticipate that manufacturers will be holding steady on new lease payments despite the uptick in demand for new vehicles,” said Scot Hall, Executive Vice President of Wantalease.com. “With the biggest shopping holidays of the year quickly approaching, its possible manufacturers may have increased prices entering December to make promotional offers seem more attractive to holiday shoppers.”

Other vehicles that experienced payment decreases for the month of December include the Audi A3, the Toyota Corolla and the Volkswagen Jetta. The A3 decreased by -11.26%, bringing monthly payments to $294 per month, the Corolla decreased by -7.56% bringing monthly payments to $189 and the Jetta decreased by -4.07%, bringing payments to $229 per month.

Wantalease.com is a sister marketplace to Swapalease.com, the nation’s largest online marketplace for leases.

About Wantalease.com:

Headquartered in Cincinnati, Ohio, Wantalease.com is the world’s first online automotive marketplace for new car leases. For more information visit www.WantAlease.com.

Press Contact:
Erica Olson
Merit Mile
[email protected]
O – 561-362-8888